Evidence map›Paper›PMID 28924035›Full record

ArticleGenes & development2017

STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ.

Chaoyong He, Shayna C Medley, Jang Kim, Chengyi Sun, Hae Ryong Kwon, Hiromi Sakashita, Yair Pincu, Longbiao Yao, Danielle Eppard, Bojie Dai and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Corneal Vascularization Associated With a Novel PDGFRB Variant.Investigative ophthalmology & visual science · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Frontiers in pharmacology · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Chaoyong HeCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Shayna C MedleyCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Jang KimCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Chengyi SunCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.ORCID 0000-0001-8500-1878
Hae Ryong KwonCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Hiromi SakashitaCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Yair PincuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Longbiao YaoCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Danielle EppardCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Bojie DaiDepartment of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
William L BerryDepartment of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Timothy M GriffinAging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Lorin E OlsonCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.ORCID 0000-0003-2168-7836
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USChina Pharmaceutical University · CN

Funding

Understanding connective tissue development and disease with PDGFR-driven..... P20GM103636 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2013 to 2023
$26.9M
Interdisciplinary research in vascular biologyP20GM103441 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2012 to 2014
$7.3M
Pilot ProjectP30GM114731 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2016 to 2020
$6.5M
PDGF-regulated cell fate and dermal fibrosisR01AR070235 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI OLSON, LORIN E · 2016 to 2020
$1.9M
NIAMS NIH HHS R01 AR070235NIGMS NIH HHS P20 GM103441NIGMS NIH HHS P20 GM103636NIGMS NIH HHS P30 GM114731
6 · The paper itself

Abstract

Platelet-derived growth factor (PDGF) acts through two conserved receptor tyrosine kinases: PDGFRα and PDGFRβ. Gain-of-function mutations in human

Indexed as

MutationAdipose TissueAnimalsAortaAtrophyBone and BonesFemaleFibroblastsFibrosisGrowth DisordersHyperplasiaInflammationInterferonsMaleMiceMice, KnockoutInterferonsReceptor, Platelet-Derived Growth Factor betaStat1 protein, mouseSTAT1 Transcription Factoradipose tissuedermisfibrosisinflammationinterferonskeletonSTAT

Identifiers

PMID28924035
PMCPMC5647937
OpenAlexW2754660768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.